As PD-1/PD-L1 blocking antibodies early after allo-SCT might increase the risk of GVHD [13], adoptive transfer of tumor-reactive T cells in combination with DC vaccination would be a safer adjuvant therapeutic approach early post-allo-SCT. Here, CD274 is linked to graft versus host disease.